Research and Whitepapers
Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium
This study evaluates the effectiveness of systemic treatments for advanced pleomorphic rhabdomyosarcoma, including anthracycline- and gemcitabine-based therapies, pazopanib and immunotherapy.
International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease
This study explores survival and recurrence following surgery for localized pleomorphic rhabdomyosarcoma and identifies factors associated with better patient outcomes.
Stacchiotti et al. - 2025 - How to foster new treatment development in ultra-rare tumours
Two 2024 multi-stakeholder workshops convened by the European Medicines Agency and the European Organisation for Research and Treatment of Cancer brought together regulators, clinicians, researchers and patient advocates to consider how treatment development for ultra-rare sarcomas can be advanced.
Take an active role in advancing sarcoma research. Contribute your expertise, join a working group, or support collaborative initiatives. PUSH provides a structured way to turn ideas and experience into meaningful progress.
Join our mailing list
Be informed about new working groups, research milestones, and opportunities to get involved